Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 1998

View Archived Issues

Endorex receives Japanese patent for ImmTher

Lion and Infogen establish gene identification collaboration

New data indicate Evista significantly reduces spinal fractures

Japanese market introduction announced for angiotensin II blocker

Immune Response treats first patient in phase Ib colon cancer trial

Meridian Diagnostics and Gull Laboratories enter definitive merger agreement

Fucoidan from seaweed extract shows antiulcer activity in preclinical models

Trimeris initiates patient selection and dosing in phase II trial of T-20 in HIV patients

Another SSRI success story: sertraline safe and effective in patients with panic disorder

FDA will give priority review to Nabi's reformulated H-BIG

CV Therapeutics, Incyte collaborate on cardiovascular gene research

Antiallergic and antiinflammatory agents developed at Takeda

Kyowa Hakko studies DC-107 derivatives as antitumor/antibacterial agents

Banyu claims aminopyrazoles for eating disorders, diabetes

New MMP inhibitors in early development at Ono

New uses for olanzapine: psychosis in AD patients and cognition disorders in schizophrenics

New phthalazine derivatives with antipsychotic-like properties

Wealth of clinical data support efficacy of ziprasidone

Vertex issued first U.S. patent for IMPDH inhibitors, begins phase II trials of lead inhibitor

Theratope cancer vaccine study fulfills enrollment

BTG licenses improved vaccine technology to Pasteur Merieux Connaught

First chemically synthesized ribozyme heading for human studies for cancer

Antidepressant efficacy demonstrated with amantadine

Energostim improves brain energy metabolism in infarct patients

Preclinical studies with YM-26818 indicate efficacy in ARDS, COPD

Controlled clinical trial demonstrates efficacy of cilostazol in intermittent claudication

Approved t.i.d. dosing regimen of Crixivan proves superior to b.i.d. regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...